Development of a mechanistically novel synergistic adjuvant to partner with polymyxin antibiotics
开发一种与多粘菌素抗生素配合使用的新型机械协同佐剂
基本信息
- 批准号:10481682
- 负责人:
- 金额:$ 30万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAcinetobacterAcinetobacter InfectionsAcinetobacter baumanniiAddressAdjuvantAdverse effectsAffectAnti-Bacterial AgentsAntibiotic ResistanceAntibioticsBacteremiaBinding ProteinsBiological AssayBioreactorsBloodCarbapenemsCeftriaxoneCell WallCellsCenters for Disease Control and Prevention (U.S.)ChemicalsChemosensitizationClinicalColistinCollaborationsData SetDevelopmentDoseDose FractionationDrug EffluxDrug KineticsExhibitsFamilyFermentationFrequenciesGoalsGonorrheaIn VitroInfectionKnowledgeLactamsLeadLettersLungLung infectionsMeasuresMedicalMembraneMethodologyMicrobiologyModelingMonitorMulti-Drug ResistanceMultidrug-resistant AcinetobacterMusNatural ProductsNosocomial pneumoniaOutcomePenicillin-Binding ProteinsPeptidoglycanPeptidyltransferasePeritonitisPermeabilityPharmaceutical ChemistryPharmaceutical PreparationsPhasePhenotypePlasma ProteinsPolymersPolymyxin BPolymyxin B resistancePolymyxin ResistancePolymyxinsProcessProductionPropertyProtocols documentationReducing AgentsResearchResistanceResortSepticemiaSeriesStructureStructure-Activity RelationshipTailTherapeutic IndexThigh structureToxicologyTreatment-related toxicityUrinary tract infectionWorkanalogbactericidebasebioprocesscarbapenem resistanceclinically relevantcolistin resistancecytotoxicitydesignefficacy testingflasksimprovedin vivoin vivo evaluationinhibitorlarge scale productionlead optimizationlead serieslipophilicitymoenomycin Amortalitymouse modelnephrotoxicitynovelpathogenpre-clinicalresistance mechanismscale upstandard of carestructural biologysynergismwound
项目摘要
Acinetobacter baumannii (Ab) and related spp. cause severe nosocomial pneumonia, wound, blood, and urinary
tract infections, with mortality rates ranging from 25-75%. The emergence of multidrug-resistant (MDR) Ab
isolates has made it difficult to treat with most standard-of-care antibiotics. Carbapenems have served as the
preferred therapy to treat Ab infections, however, over 50% of infections are now carbapenem-resistant Ab
(CRAB). Consequently, the WHO and CDC have classified CRAB as a PRIORITY-1 CRITICAL and URGENT
threat pathogen. Polymyxin B (PMB) and colistin have become the antibiotics of last resort to treat CRAB despite
their low therapeutic index due to potential nephrotoxicity. To address this unmet medical need, we aim to
develop an effective combination agent comprising a polymyxin potentiator and an efficacious, mechanistically
novel antibiotic, medinamycin (MedM). MedM is unaffected by clinically relevant modes of antibiotic resistance,
exhibits low FOR and provides robust synergistic bactericidal activity against Ab, including colistin-resistant,
MDR, and CRAB isolates, and is predicted to be a safe and effective antibiotic to permit lower effective doses of
PMB, thereby reducing adverse effects.
Aim 1 (Phase 1) Validate the feasibility of developing semisynthetic MedM analogs effective in
combination with PMB and/or SPR741 against polymyxinR Ab. Improve MedM bioprocess to deliver >1 g for
Aim 1 studies. Demonstrate chemical tractability. Develop the structure activity relationship (SAR) of new
analogs using MOA, FOR, microbiological activity, and cytotoxicity assays. Demonstrate in vivo efficacy of a
MedM analog + PMB against a PMBR Ab isolate in murine bacteremia infection model.
Aim 2 (Phase 2) Complete bioprocess optimization and conduct a semisynthetic lead optimization with
the goal of identifying MedM analogs with improved potency and/or drug like properties. Increase reliable
production levels of MedM to >250 mg/L using 20L bioreactors, eventually producing 30 g of MedM. Using this
material, prepare up to 150 semisynthetic analogs in an iterative fashion according to emerging SAR. Measure
Ab MIC for all compounds, and for select compounds evaluate synergistic inhibitory concentration with potential
polymyxin partners, in vitro tox and ADME, FOR, kill curves, PK and MIC90 to select polymyxin partner and
analogs to advance to in vivo testing in Aim 3.
Aim 3 (Phase 2) In vivo characterization of MedM analogs in combination with selected potentiator in
relevant mouse models of Ab infection to identify lead series of combination product. Test efficacy of
superior MedM analogs + polymyxin potentiator against a PMBR Ab clinical isolate in a mouse peritonitis infection
model, followed by a deep thigh and neutropenic mouse lung infection model. In each study, demonstrate that a
MedM analog provides statistically significant efficacy (P < 0.05) if combined with polymyxin at a sub-efficacious
dose to identify lead MedM series for combination product. Dose fractionation studies will also be performed.
鲍曼不动杆菌(Ab.)及相关种。引起严重的院内肺炎、伤口、血和尿液
肠道感染,死亡率从25%到75%不等。多药耐药抗体的出现
分离株使大多数标准护理抗生素难以治疗。碳青霉烯类一直是
治疗抗体感染的首选疗法,然而,现在超过50%的感染是碳青霉烯类耐药抗体
(螃蟹)。因此,世界卫生组织和疾控中心将螃蟹列为优先事项-1关键和紧急
威胁病原体。多粘菌素B(PMB)和粘菌素已成为治疗螃蟹的最后手段
由于潜在的肾毒性,其治疗指数较低。为了解决这一未得到满足的医疗需求,我们的目标是
研制一种由多粘菌素增强剂和一种有效的、机械的
新型抗生素--麦迪霉素(Medm)。MedM不受临床相关抗生素耐药性模式的影响,
对抗体,包括对粘菌素耐药的抗体,表现出低的杀菌活性并提供强大的协同杀菌活性,
MDR和螃蟹分离株,预计将是一种安全有效的抗生素,允许较低有效剂量的
港口及航运局,从而减少不利影响。
目标1(阶段1)验证开发有效的半合成MedM类似物的可行性
PMB和/或SPR741联合抗多粘菌素R抗体。改进MedM生物工艺以交付1克用于
目的1研究。证明化学物质的易操纵性。发展新的构效关系(SAR)
类似物使用MOA、FOR、微生物活性和细胞毒性测定。在体内展示了一种
MedM类似物+PMB在小鼠菌血症感染模型中对PMBR抗体分离株的作用
目标2(阶段2)完成生物工艺优化,并进行半合成铅优化
目的是确定具有更高效力和/或类药物特性的MedM类似物。提高可靠性
使用20L生物反应器,生产水平为250 mg/L的MedM,最终生产30 g MedM。使用这个
材料,根据正在出现的SAR以迭代的方式准备多达150个半合成类似物。量测
对所有化合物的最低抑菌浓度,对于选定的化合物,用潜在的评价协同抑制浓度
多粘菌素配对,体外TOX和ADME,用于杀伤曲线,PK和MIC90选择多粘菌素配对和
类似物将在AIM 3中进行体内测试。
目的3(阶段2)在体内表征MedM类似物与所选增强剂的结合
建立相关小鼠抗体感染模型,鉴定铅系列结合产物。测试药效
高级药物类似物+多粘菌素增强剂抗PMBR抗体临床分离株在小鼠腹膜炎感染中的作用
建立小鼠大腿深部和中性粒细胞减少的肺部感染模型。在每项研究中,证明
如果与多粘菌素联合使用效果不佳,MedM类似物在统计学上有显著疗效(P<;0.05
用于联合产品的铅MedM系列的剂量识别。还将进行剂量分级研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Terry Roemer其他文献
Terry Roemer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Terry Roemer', 18)}}的其他基金
Development of a novel broad spectrum antifungal therapeutic targeting Glycosylphosphatidylinositol (GPI) biosynthesis and cell wall biogenesis
开发一种针对糖基磷脂酰肌醇 (GPI) 生物合成和细胞壁生物合成的新型广谱抗真菌治疗药物
- 批准号:
10759723 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Development of a mechanistically novel Gram-negative antibiotic targeting MsbA-mediated Lipopolysaccharide Biogenesis
开发一种机制新颖的革兰氏阴性抗生素,靶向 MsbA 介导的脂多糖生物发生
- 批准号:
10584170 - 财政年份:2022
- 资助金额:
$ 30万 - 项目类别:
Characterization of MsbA inhibitors as potential antibiotic leads to treat carbapenem-resistant Enterobacteriaceae (CRE)
MsbA 抑制剂作为潜在抗生素的特性可用于治疗耐碳青霉烯类肠杆菌 (CRE)
- 批准号:
10242174 - 财政年份:2020
- 资助金额:
$ 30万 - 项目类别:
Characterization of MsbA inhibitors as potential antibiotic leads to treat carbapenem-resistant Enterobacteriaceae (CRE)
MsbA 抑制剂作为潜在抗生素的特性可用于治疗耐碳青霉烯类肠杆菌 (CRE)
- 批准号:
9978345 - 财政年份:2020
- 资助金额:
$ 30万 - 项目类别:
Development of WecA-targeting immune potentiators to treat carbapenem-resistant Enterobacteriaceae (CRE) infections
开发 WecA 靶向免疫增强剂来治疗碳青霉烯类耐药肠杆菌 (CRE) 感染
- 批准号:
10415522 - 财政年份:2019
- 资助金额:
$ 30万 - 项目类别:
Development of WecA-targeting immune potentiators to treat carbapenem-resistant Enterobacteriaceae (CRE) infections
开发 WecA 靶向免疫增强剂来治疗碳青霉烯类耐药肠杆菌 (CRE) 感染
- 批准号:
10470327 - 财政年份:2019
- 资助金额:
$ 30万 - 项目类别:
Development of a novel agent to treat antimicrobial resistant Neisseria gonorrhoeae
开发治疗耐药性淋病奈瑟菌的新型药物
- 批准号:
9620389 - 财政年份:2018
- 资助金额:
$ 30万 - 项目类别:
Restoring Beta-lactam efficacy against methicillin-resistant Staphylococci
恢复 β-内酰胺对耐甲氧西林葡萄球菌的功效
- 批准号:
9814432 - 财政年份:2018
- 资助金额:
$ 30万 - 项目类别:
Development of a PO-administered beta-lactam-tarocin combination agent to treat methicillin susceptible and methicillin resistant Staphylococci
开发用于治疗甲氧西林敏感和甲氧西林耐药葡萄球菌的 PO 给药 β-内酰胺-塔罗辛组合药物
- 批准号:
10662488 - 财政年份:2018
- 资助金额:
$ 30万 - 项目类别:
Development of a novel agent to treat antimicrobial resistant Neisseria gonorrhoeae
开发治疗耐药性淋病奈瑟菌的新型药物
- 批准号:
9913150 - 财政年份:2018
- 资助金额:
$ 30万 - 项目类别:
相似国自然基金
共生细菌Acinetobacter soli来源精氨酸级联味觉受体NlGR21介导褐飞虱抗烯啶虫胺的分子机制
- 批准号:JCZRYB202500693
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
细菌Acinetobacter sp.挥发物在瓜蚜蜜露调控龟纹瓢虫产卵定位中的作用研究
- 批准号:32302339
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
Acinetobacter sp. AS23菌株介导茶籽象耐受茶皂素毒性的分子机制解析
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 30万 - 项目类别:
Research Grant
Generative machine learning for narrow spectrum antibiotic discovery against Acinetobacter baumannii
生成机器学习用于发现针对鲍曼不动杆菌的窄谱抗生素
- 批准号:
477936 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Operating Grants
Conserved structural dynamics of outer-membrane channels in Acinetobacter baumannii as potential drug targets
鲍曼不动杆菌外膜通道的保守结构动力学作为潜在的药物靶点
- 批准号:
494854 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Operating Grants
Defining key players at the host-pathogen interface during Acinetobacter baumannii infection
定义鲍曼不动杆菌感染期间宿主-病原体界面的关键参与者
- 批准号:
488684 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Operating Grants
Study of clinically over-expressed and chimeric RND multidrug efflux pumps from Acinetobacter baumannii and Pseudomonas aeruginosa
鲍曼不动杆菌和铜绿假单胞菌临床过表达和嵌合 RND 多药外排泵的研究
- 批准号:
23K14346 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Biomimetic Macrophage Membrane-Coated Nanosponges: A Novel Therapeutic for Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Hospital-Associated Pneumonia
仿生巨噬细胞膜包被的纳米海绵:一种治疗多重耐药铜绿假单胞菌和鲍曼不动杆菌医院相关肺炎的新疗法
- 批准号:
10674406 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Using strain history to improve prediction of the evolution of antimicrobial resistance in Acinetobacter baumannii
利用菌株历史改进对鲍曼不动杆菌抗菌药物耐药性演变的预测
- 批准号:
10677362 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Inhibitors of adaptive efflux mediated resistance in Acinetobacter baumannii
鲍曼不动杆菌适应性外排介导的耐药性抑制剂
- 批准号:
10625029 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Creation of Active Substances from Deep-sea Actinomycetes to Disrupt Drug-Resistant Acinetobacter spp.
从深海放线菌中产生活性物质来破坏耐药不动杆菌属。
- 批准号:
22K19442 - 财政年份:2022
- 资助金额:
$ 30万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Identifying niche specific adaptations in Acinetobacter baumannii
鉴定鲍曼不动杆菌的生态位特异性适应
- 批准号:
10596620 - 财政年份:2022
- 资助金额:
$ 30万 - 项目类别:














{{item.name}}会员




